Welcome to our dedicated page for PROVECTUS BIOPHARMACEUTICALS SEC filings (Ticker: PVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PROVECTUS BIOPHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PROVECTUS BIOPHARMACEUTICALS's regulatory disclosures and financial reporting.
Provectus Biopharmaceuticals reported a net loss of $988,716 for the quarter and $2,289,665 for the six months ended June 30, 2026, both markedly lower than the prior-year periods as operating expenses declined. Research and development spending fell sharply, mainly from reduced clinical and manufacturing activity, while general and administrative costs also decreased on lower professional fees, payroll, legal and stock-based compensation.
Cash increased to $1,156,915 from $251,291 at year-end 2025, helped by $1,695,000 of new 2025 convertible notes and $75,000 raised at majority-owned subsidiary VisiRose, but the company still had a working capital deficit of $6,338,261 and an accumulated deficit of $265,126,832. Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern and stated that continued operations depend on successfully developing its RBS-based drug candidates and raising additional capital, including through its 2025 Financing convertible note program.
An amended beneficial ownership report states that Edward Pershing, Chairman and CEO of Provectus Biopharmaceuticals, Inc., beneficially owns 52,441,275 shares of common stock, representing 11.61% of the company’s common shares. The percentage is based on 420,279,879 shares outstanding as of June 30, 2026 plus shares underlying his options, preferred stock and convertible notes.
Pershing’s position includes directly held stock, retirement plan holdings, 16,980,144 stock options exercisable within 60 days, and common shares issuable from Series D‑1 convertible preferred and remaining notes. The issuer has issued to him an aggregate $7,512,500 principal amount of secured convertible promissory notes since 2018; $6,642,500 has converted into Series D‑1 preferred at $2.862 per share, including recent automatic conversions in May and June 2026 and a new $15,000 note purchase on May 28, 2026.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing filed an updated Form 4 that corrects a past reporting error rather than recording a new transaction. The filing adjusts his reported holdings of Series D-1 Convertible Preferred Stock, with the footnote stating the change "does not reflect a transaction."
After this correction, Pershing is shown holding 2,866,761 shares of Series D-1 Convertible Preferred Stock. Each preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under the certificate of designation terms.
PROVECTUS BIOPHARMACEUTICALS, INC. reported that President and director Dominic Rodrigues received a grant of 45,860 shares of Series D-1 Convertible Preferred Stock at a price of $0.00 per share. Each preferred share is convertible into 10 shares of common stock, representing 458,600 underlying common shares. After this grant, Rodrigues holds 1,383,736 shares of Series D-1 Preferred Stock, which will automatically convert into common stock on December 31, 2028 unless converted earlier under the series’ terms.
PROVECTUS BIOPHARMACEUTICALS, INC. director John Lacey III reported receiving a grant of 48,917 shares of Series D-1 Convertible Preferred Stock on June 30, 2026. The shares were awarded at a price of $0.00 per share as a compensation-related acquisition.
Each Series D-1 share is convertible into 10 shares of common stock, representing 489,170 underlying common shares for this grant. After this award, Lacey holds 228,509 shares of Series D-1 Convertible Preferred Stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation.
Provectus Biopharmaceuticals director Bailey Webster received a grant of 48,917 shares of Series D-1 Convertible Preferred Stock. The shares were acquired on June 30, 2026 at a stated price of $0.00 per share as a grant or award, not an open-market transaction.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 Preferred Stock will automatically convert into common stock on December 31, 2028, unless converted earlier under the terms of its Certificate of Designation. Following this grant, Webster directly holds 207,535 shares of Series D-1 Preferred Stock.
Provectus Biopharmaceuticals, Inc. is converting accrued but unpaid directors’ fees into equity. The Board approved turning $542,500.00 of fees owed through June 30, 2026 into shares of the company’s Series D-1 Preferred Stock at $2.862 per share.
This will result in 189,554 shares of Series D-1 Preferred Stock, which are convertible into 1,895,540 shares of common stock. The preferred shares are being issued to satisfy outstanding cash fees and are not a separate award under the 2024 Equity Compensation Plan.
Provectus Biopharmaceuticals, Inc. held its annual stockholder meeting on June 18, 2026, where five proposals were decided. Stockholders elected four directors to one‑year terms, with each nominee receiving over 191 million votes in favor, plus 131,619,889 broker non‑votes reported on this item.
They approved an advisory vote on executive compensation, with 190,162,705 votes for and 16,667,960 against, and ratified CBIZ CPAs P.C. as independent registered public accounting firm for 2026 with 329,742,597 votes for. Stockholders also authorized the board to implement a reverse stock split of common and certain preferred stock at a ratio between 1‑for‑10 and 1‑for‑50, and to proportionally reduce authorized common and preferred shares using the same ratio once selected by the board.
Provectus Biopharmaceuticals, Inc. filed a current report describing information to be shared at its June 18, 2026 annual meeting of stockholders. The company plans to update stockholders on clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities.
The accompanying 2026 Annual Meeting of Stockholders presentation slides are attached as Exhibit 99.1. This material is furnished under Regulation FD and is not deemed filed under the Securities Exchange Act of 1934.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing exercised convertible securities to increase his common stock holdings. On the transactions date, an 8% unsecured convertible promissory note converted into 9,436 shares of Series D-1 Convertible Preferred Stock at $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 94,360 additional common shares. After these derivative exercises and conversions, Pershing directly owns 2,857,285 shares of common stock. These were conversions of existing securities, not open-market purchases or sales.